Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Other Operating Expenses (2023 - 2025)

Mangoceuticals' Other Operating Expenses history spans 3 years, with the latest figure at -$241976.0 for Q4 2025.

  • On a quarterly basis, Other Operating Expenses fell 126.78% to -$241976.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $14.5 million, a 171.45% increase, with the full-year FY2025 number at -$125624.0, down 102.35% from a year prior.
  • Other Operating Expenses hit -$241976.0 in Q4 2025 for Mangoceuticals, down from $7.3 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for MGRX hit a ceiling of $7.3 million in Q3 2025 and a floor of -$241976.0 in Q4 2025.
  • Historically, Other Operating Expenses has averaged $2.3 million across 3 years, with a median of $1.8 million in 2023.
  • The widest YoY moves for Other Operating Expenses: up 453.0% in 2025, down 126.78% in 2025.
  • Tracing MGRX's Other Operating Expenses over 3 years: stood at $1.9 million in 2023, then tumbled by 52.13% to $903710.0 in 2024, then crashed by 126.78% to -$241976.0 in 2025.
  • Business Quant data shows Other Operating Expenses for MGRX at -$241976.0 in Q4 2025, $7.3 million in Q3 2025, and $4.1 million in Q2 2025.